Background {#Sec1}
==========

Although the prevalence of chronic constipation varies in different studies (2--27%) \[[@CR1]\], the 2017 National Survey of Basic Life Surveys in Japan reported that the rate of constipation-related complaints was 2.5% in males and 4.6% in females \[[@CR2]\]. Studies in Japan and the United States have shown that the prevalence of constipation increases with age in both sexes and is higher in females \[[@CR1], [@CR3]\]. A higher prevalence of constipation has also been reported in non-whites than in whites, and in those with fewer years of education or a lower socioeconomic status \[[@CR1]\]. With regard to risk factors, no relationship between body mass index (BMI) and constipation has been observed, although eating significantly less food at breakfast has been reported in constipated children \[[@CR4], [@CR5]\]. While moderate exercise does not alter intestinal function, vigorous exercise such as jogging is considered to enhance transit through the digestive tract \[[@CR6]\]. There is evidence that vigorous exercise can relieve constipation in the elderly \[[@CR7]--[@CR9]\]. Sleeplessness, or staying awake for long periods of time, is also reported among people with constipation \[[@CR10], [@CR11]\]. Johanson (1998) was the first to report that a low temperature was one of the global environmental risk factors for constipation \[[@CR12]\]. In contrast, there are no reports of risk factors for each constipation drug used by the population, or based on climate, and socioeconomic factors. The open Japanese National Database (NDB) was publicly released to researchers in 2011, and the number of studies using the NDB has grown rapidly \[[@CR13]\]. The aim of this study was to investigate risk factors for constipation drug use with an emphasis on residential and environmental factors using the open Japanese National Database (NDB).

Methods {#Sec2}
=======

Study type {#Sec3}
----------

Ecological study.

Data source (for this secondary data source) {#Sec4}
--------------------------------------------

Data were obtained from the 2016 open Japanese NDB which was published by the Ministry of Health, Labor and Welfare \[[@CR14]\]. Data pertaining to the population (age \[\> 65 years\], sex, population density, and total crime rate), climate (average outside temperature and humidity, precipitation in capital cities, and mean elevation above sea level), and socioeconomic factors (average monthly and total family income) for all 47 prefectures in Japan in 2016 were obtained from the online database of the Ministry of Internal Affairs and Communications and Geospatial Information Authority of Japan \[[@CR15], [@CR16]\].

Data extraction {#Sec5}
---------------

The extracted data from NDB included the following: (1) the number of population-based health insurance claims (prescriptions) for prescription medicines (e.g., laxatives including magnesium-based agents, stimulant laxatives, lactulose, herbal medicines, antihypertensives, and vasodilators), (2) fecal interventions (e.g., enemas, disimpaction treatments), (3) prescriptions for suppositories and enemas, (4) specific medical check-ups (e.g., for BMI, hemoglobin A1c, and abdominal circumference measurements), (5) responses to questionnaires (e.g., related to insomnia, antihypertensives, smoking, drinking, eating, and exercise habits) and (6) psychiatric specialty therapy.

Inclusion and exclusion criteria {#Sec6}
--------------------------------

Magnesium sulfate, which was originally classified for laxative and enema use, was categorized as a magnesium laxative for the purposes of the analysis in this study. Antihypertensives included angiotensin II receptor blockers (e.g., telmisartan), 1 blockers (e.g., doxazosin), blockers (e.g., carvedilol), angiotensin-converting enzyme inhibitors (e.g., enalapril), and some calcium (Ca) blockers (e.g., amlodipine) and vasodilators, including nitrate (e.g., isosorbide mononitrate). To minimize ecological fallacy, the extent and severity to which constipation affected the population were determined using the number of health insurance claims (prescriptions) for the treatment of constipation per 1000 people. The above-reported risk factors of constipation were included as variables (sex, aging, environment, socioeconomic status, habits, and some constipating drugs \[e.g., antihypertensives and vasodilators\]). Low outside temperature was found to be a significant risk factor for constipation drug use. However, because room temperature is not always associated with outside temperature, depending on location, we searched inside room temperature in 2016 to determine which temperature (outside or inside) was the dominant factor affecting constipation drug use; inside room temperature in 2016 was not available. Because the correlation coefficient of outside temperature between 2010 and 2016 was adequately high (R^2^ = 0.99), we decided to use inside room temperature in 2010 \[[@CR17]\], combined with the 2016 dataset. Lactulose is approved for not only constipation but also hepatic hyperammonemia and defecation for gynecologic surgery in Japan. Moreover, because we could not differentiate lactulose for constipation from other indications, we decided to exclude all lactulose from this study.

Sampling technique employed {#Sec7}
---------------------------

Cluster sampling (Japanese population and/or specific medical check-ups; examinees were between 40 and 74 years old in 2016).

### Statistical analysis and other {#Sec8}

SPSS Statistics 24.0 (IBM Corp., Armonk, NY) was used to calculate correlation coefficients between the number of population-based insurance claims (prescriptions) per 1000 people for each drug for constipation. Statically significant variables (*p* \< 0.05) were extracted for multiple linear regression (MLR) analysis. MLR was subsequently performed using a stepwise method to exclude the confounding variables and identify the independent predictors of constipation drug use.

Results {#Sec9}
=======

Table [1](#Tab1){ref-type="table"} shows the means and SDs of population, climate, and socioecological variables in 47 Japanease prefectures. The mean rate of Japanese people who were \> 65 years (aging) was 29.6%. The Japanese population had slightly more females than males. The average number of insurance claims (prescriptions) summarized by constipation and cardiovascular drug use by people is shown in Table [2](#Tab2){ref-type="table"}. In this study lactulose, herbal medicines, and novel drugs (e.g., lubiprostone) were excluded from the analysis. Pearson correlation coefficients (r) are shown in Table [3](#Tab3){ref-type="table"}. Prescriptions for magnesium laxatives significantly correlated with aging (*r* = 0.58), vasodilators (*r* = 0.53), female sex (*r* = 0.43), and antihypertensives (*r* = 0.39) and were inversely correlated with eating ≤2 h before bedtime (*r* = − 0.37), total crime rate (*r* = − 0.33), insomnia (*r* = − 0.33), and population density (*r* = − 0.31), etc. Table 1Variables assessed in the population (*N* = 47 Japanese prefectures)**VariablesMean± SD**Age, \> 65 years (%)29.62.9Female: Male1:10.0Population density (km^2^)655.31194.4Total crimes/10 months per 1000 people5.41.8Average outside temperature (°C)16.22.4Average room temperature (°C)18.80.9Average humidity (%)70.64.2Precipitation in capital city (mm/year)1609.2418.0Mean elevation above sea level (m)361.1216.8Average income (thousand yen) Males298.328.9 Females211.519.0 Total household5189.1520.6 Total worker household6031.0549.4Obese, BMI \> 25 kg/m^2^ (%)26.72.6Weight loss, BMI \< 20 kg/m^2^ (%)17.81.7Insomnia (%)34.34.1Hyperglycemia (%)7.00.6Antihypertensive drug use (%)21.52.3Waist circumference \> 90 cm (%)21.11.7Smoking (%)22.71.9Daily alcohol intake (%)27.82.2No breakfast (%)14.62.4Eating after dinner (%)15.92.3Eating ≤2 h before bedtime (%)25.82.7Eating rapidly (%)31.11.8Walking fast (%)45.04.1Walking \> 1 h (%)39.95.530-min of vigorous exercise (%)27.23.3Psychiatric specialty therapy per 1000 people891.7219.7*BMI* body mass indexTable 2Health insurance claims (prescriptions) among residents in all Japanese prefectures (*N* = 47)**Average claims (prescriptions) per 1000 people, n± SDMinimumMaximum**Constipation drugs Magnesium33,431609519,53743,859 Stimulant laxatives16,6034251818131,672 Lactulose35558208205420 Herbal medicines10,3331826182616,475 Fecal interventions37111863 Suppositories and enemas1316053292Cardiovascular drugs Antihypertensives49,196680534,44071,422 Vasodilators47,037699034,21461,601Table 3Relationships between variables and drugs to relieve constipation (*N* = 47 prefectures in Japan)**Pearson correlation coefficients by type of drug used to relieve constipationMagnesiumStimulant laxativeFecal interventionSuppositories and enemas**Aging (\> 65 years)0.583^\*\*^0.693^\*\*^0.552^\*\*^0.303^\*^Vasodilator claims/prescriptions (per 1000 people)0.526^\*\*^0.667^\*\*^0.308^\*^0.2Female gender0.434^\*\*^0.562^\*\*^0.592^\*\*^0.453^\*\*^Antihypertensive claims/prescriptions (per 1000 people)0.389^\*\*^0.794^\*\*^0.338^\*^0.1Eating ≤2 h before bedtime−0.366^\*^− 0.288^\*^− 0.372^\*\*^− 0.1Total crimes/10 month (per 1000 people)− 0.334^\*^− 0.515^\*\*^− 0.386^\*\*^− 0.2Insomnia− 0.327^\*^− 0.2− 0.326^\*^− 0.1Population density (per km^2^)−0.308^\*^− 0.348^\*^− 0.405^\*\*^− 0.2Average humidity0.293^\*^0.353^\*^0.310^\*^0.2Psychiatric specialty therapy (per 1000 people)0.20.20.333^\*^0.3Antihypertensives0.20.424^\*\*^0.10.2Daily alcohol intake0.10.511^\*\*^0.3−0.1Eating after dinner0.10.20.291^\*^0.344^\*^Mean elevation above sea level0.10.00.20.0Eating rapidly0.1−0.20.10.317^\*^Weight loss (BMI \< 20 kg/m^2^)0.0−0.20.2−0.230-min of vigorous exercise0.0−0.442^\*\*^− 0.288^\*^0.2Average outside temperature0.0−0.622^\*\*^−0.20.1Hyperglycemia0.00.20.10.2Precipitation in capital city−0.1−0.10.0−0.1Waist circumference \> 90 cm−0.1− 0.1−0.20.1Obese (BMI \> 25 kg/m^2^)−0.10.1−0.20.1Total worker household income−0.2−0.2− 0.299^\*^−0.355^\*^Walking \> 1 h− 0.2− 0.1− 0.1− 0.1Average room temperature−0.20.364^\*^0.1−0.1Total household income−0.2− 0.2− 0.3−0.353^\*^Smoking−0.20.489^\*\*^0.0− 0.3Female average income−0.2− 0.522^\*\*^− 0.343^\*^−0.2No breakfast−0.2− 0.334^\*^− 0.20.0Walking fast−0.2−0.2− 0.20.1Male average income−0.3− 0.513^\*\*^−0.380^\*\*^− 0.3*BMI* body mass index\**p* \< 0.05, \*\**p* \< 0.01

Stimulant laxative prescriptions were significantly correlated with antihypertensive drug uses (*r* = 0.79), aging (*r* = 0.69), vasodilator prescriptions (*r* = 0.67), female sex (*r* = 0.56), daily alcohol intake rate (*r* = 0.51), smoking rate (*r* = 0.49), antihypertensive prescriptions (*r* = 0.42), average room temperature (*r* = 0.36), and average outside humidity (*r* = 0.35) etc., and inversely correlated with average outside temperature (*r* = − 0.62), total crime (*r* = − 0.52), average income (*r* = − 0.51), 30-min of vigorous exercise (*r* = − 0.44), population density (*r* = − 0.35), no breakfast (*r* = − 0.33), and eating ≤2 h before bedtime (*r* = − 0.29), etc.

For fecal interventions, significant positive correlations were observed with aging (*r* = 0.55), female sex (*r* = 0.59), average outside humidity (*r* = 0.31), antihypertensives (*r* = 0.34), and psychiatric specialty therapy per 1000 people (*r* = 0.33). Negative correlations were noted for population density (*r* = − 0.41), total crime rate (*r* = − 0.38), average incomes (*r* = − 0.38 and − 0.34), eating ≤2 h before bedtime (*r* = − 0.37), insomnia (*r* = − 0.33), and 30-min of vigorous exercise (*r* = − 0.29).

Prescriptions for suppositories and enema correlated significantly with female sex (*r* = 0.45), total household income (*r* = 0.35), and eating after dinner (*r* = 0.34), etc.

Overall, risk factors for constipation-related treatments included population factors (aging, female sex, daily alcohol intake, smoking, antihypertensives, and eating after dinner) and climate factors (average outside humidity and average room temperature). In contrast, preventive factors for constipation-related treatments included factors related to the population (eating ≤2 h before bedtime, 30-min of vigorous exercise, and no breakfast), climate (outside temperature), and socioecological aspects (total crime rate, population density, and average incomes). As the difference of the values of these factors must be dependent on the place of residence and dietary habits that must differ by location, to exclude these confounding factors, MLR was performed using each significant variable that appeared explanatory.

Aging was observed to be the only significant risk factor for the use of magnesium laxatives (F-value 23.2, R^2^ 0.34, partial slope \[β\] = 1241.0; Table [4](#Tab4){ref-type="table"}). Plotted data between aging and magnesium claims (prescriptions) per 1000 people is shown in Fig. [1](#Fig1){ref-type="fig"}. Female sex and antihypertensives were independent risk factors for stimulant laxative prescriptions (β =44,547.0 and 0.2), average outside temperature and 30-min of vigorous exercise were independent preventive factors (β = − 616.8 and − 219.1) but not room temperature (F-value 4.9, R^2^ 0.81, Table [5](#Tab5){ref-type="table"}). Plotted data between average outside temperature and stimulant laxative claims per 1000 people are shown in Fig. [2](#Fig2){ref-type="fig"}. Female sex was an independent risk factor for fecal interventions (β =146.8). Insomnia and 30-min of vigorous exercise were observed to be independent preventive factors for fecal interventions (β = − 0.7 and − 1.2; F-value 4.5, R^2^ 0.50, Table [6](#Tab6){ref-type="table"}). Table 4Multiple linear regression analysis for magnesium laxatives**Partial slope \[β\]*p*** **value95.0% Confidence intervalLower limitUpper limit**Aging1241.00.00\*\*722.01759.9\*\**p* \< 0.01Fig. 1Aged persons (%) and magnesium prescription claims (prescriptions) per 1000 peopleTable 5Multiple linear regression analysis for stimulant laxatives**Partial slope \[β\]*p*** **value95.0% Confidence intervalLower limitUpper limit**Female gender44,547.00.00\*\*27,991.261,102.8Antihypertensive claims (prescriptions) per 1000 people0.20.00\*\*0.090.34Average outside temperature−616.80.00\*\*− 958.4− 275.130-min of vigorous exercise−219.10.03\*− 419.6− 18.6\**p* \< 0.05, \*\**p* \< 0.01Fig. 2Average outside temperature and stimulant laxative prescriptions claims (prescriptions) per 1000 peopleTable 6Multiple linear regression analysis for fecal interventions**Partial slope \[β\]*p*** **value95.0% confidence intervalLower limitUpper limit**Female gender146.80.00\*\*85.5208.1Insomnia−0.70.04\*−1.3−0.030-min of vigorous exercise−1.20.00\*\*−1.9−0.4\* *p* \< 0.05, \*\* *p* \< 0.01

Female sex was an independent risk factor for prescriptions for suppositories and enemas (β = 656.5; F-value 11.6, R^2^ 0.21, Table [7](#Tab7){ref-type="table"}). Table 7Multiple linear regression analysis for suppositories and enemas**Partial slope \[β\]*p*** **value95.0% confidence intervalLower limitUpper limit**Female gender656.50.00\*\*268.41044.5\*\**p* \< 0.01

Discussion {#Sec10}
==========

Here, we report the results of an ecological analysis of health insurance claims (prescriptions) for the alleviation of constipation using the Japanese NDB dataset. Previous studies have reported the association of aging with constipation \[[@CR1], [@CR3]\]. Foremost, our results showed that aging was associated with the number of magnesium laxative prescriptions but not the number of other drugs (Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"}). To the best of our knowledge, no reports have described the responses of age-related constipation to magnesium laxatives, particularly with regard to the effects of risk factors other than aging. Female sex was an independent risk factor for the use of stimulant laxatives, fecal interventions, and prescriptions for suppositories and enemas, consistent with previous reports \[[@CR1], [@CR3]\]. Johanson was first to report that low temperatures were one of the global environmental risk factors for constipation \[[@CR12]\]. In this study, we showed that outside temperature and vigorous exercise were independent preventive factors for stimulant laxative prescriptions (Table [5](#Tab5){ref-type="table"}). However, the mechanisms through which outside temperature and vigorous exercise affect stimulant laxative use are not clear. In previous reports, internal body temperature has been shown to be synchronized with outside temperature \[[@CR18], [@CR19]\], increased with metabolic rate in dogs and humans \[[@CR20], [@CR21]\] and with vigorous exercise \[[@CR22]\], and decreased with aging \[[@CR23]\]. Additionally, intestinal contraction or transit may affect in low internal temperature in humans, as demonstrated in an ex-vivo study \[[@CR24]\] and may improve with vigorous exercise or external body warming using lumbar application of a 40 °C hot compress in women with constipation \[[@CR22], [@CR25]\]. These reports have suggested that aging may be a necessary risk factor and that low outside temperature could be an added factor augmenting the need for stimulant laxatives. Antihypertensives were also an independent risk factor for stimulant laxative prescriptions. Antihypertensive use, rather than vasodilator use, may be a risk factor for constipation drug use. In this study, there were no associations between use of drugs to relieve constipation and underlying diseases (obesity, weight loss, insomnia, hyperglycemia, and psychiatric specialty therapy) and socioeconomic status (income and educational environment).

There were some limitations in this study. The first was that the number of health insurance claims (prescriptions) related to prescriptions for the treatment of constipation were used as a surrogate measure of the extent and severity to which constipation affected the population. And in this study lactulose, herbal medicines, and several novel drugs available from 2012 were excluded. This type of ecological study has inherent problems related to extrapolation of relationships among groups to individuals. We considered using other statistical analysis including multilevel modelling (MLM) techniques, which would overcome the ecological fallacy and help to examine the contextual effects. However, because they required information at the individual level, we thought that MLM and other analysis could not be applied in this study. The second limitation is that the room temperatures (not an independent risk factor) used in this analysis were derived from 2010 data sourced via an internet search \[[@CR17]\]. In this study, we evaluated the correlation coefficient of outside temperature between 2010 and 2016 (R^2^ = 0.99, Supplementary Fig. 1). Our result supported the validity of using inside room temperature in 2010 in our analysis of the 2016 dataset. The third limitation is that this study was based on 2016 data; however, it is the latest available data set of its kind. Finally, some potential confounding factors (e.g., other constipation-related diseases or drug use) were not included in our analysis.

Conclusion {#Sec11}
==========

In this study, we performed an ecological analysis of drugs used to alleviate constipation in the Japanese population. Our findings showed that magnesium-based mediation alone was associated with aging and that stimulant laxative use was associated with female sex, lower outside temperature, antihypertensives, and vigorous exercise. Further studies are required to evaluated the causative relationships among these factors.
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